About Ensysce Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://ensysce.com/
Frequently Asked Questions
What is the 52-week range for ENSC?
The 52-week high is $2.75 and the 52-week low is $0.23.
What is the P/E ratio for ENSC?
The P/E ratio data is currently unavailable.
What is the dividend yield for ENSC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -374.96%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -280.48%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.18.
Analyst Recommendation Trends
Wall Street analyst consensus for ENSC over the last few months:
Latest ENSC News
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company's newest drug candi
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026.
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-07 | GOWER BOB G | +400,000 | $0.495 | $198,000 |
| 2026-04-23 | GOWER BOB G | +254,307 | - | - |
| 2026-04-23 | GOWER BOB G | +508,614 | $0.484 | $246,169 |